课题基金 / 基金详情

Mechanisms of Berberine for the Treatment of Non-Alcoholic Fatty Liver Disease

Mechanisms of Berberine for the Treatment of Non-Alcoholic Fatty Liver Disease
小檗碱治疗非酒精性脂肪肝的机制
批准号:
10046281
负责人:
HUIPING Rose ZHOU
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-10-01 至 2021-09-30

项目摘要

项目成果

HUIPING Rose ZHOU的其他基金

相似基金

相关文献

中文摘要
翻译
非酒精性脂肪性肝病(NAFLD)已成为最常见的慢性肝病,尤其是 在美国退伍军人中。非酒精性脂肪肝与炎症、胰岛素抵抗、血脂异常和 代谢综合征。NAFLD和非酒精性脂肪性肝炎(NASH)研究的最新进展表明 肠道微生物区系通过影响宿主代谢平衡在疾病进展中发挥重要作用 和免疫反应。“代谢性内毒素血症”与循环内毒素水平升高 (脂蛋白)由于肠屏障功能的破坏和游离长链脂肪酸(FFA)与 刺激全身炎症和胰岛素抵抗,这两者都与 非酒精性脂肪肝的发展和进展。尽管脂多糖/游离脂肪酸诱导肝损伤的机制 脂毒性仍不完全清楚,内毒素/游离脂肪酸诱导炎性细胞因子如肿瘤坏死因子-1的表达。 与激活内质网应激信号通路,称为未折叠蛋白 回应(普遍定期审议)是主要的贡献者。此外,微小RNA(MiR)、小非编码RNA(~22 核苷酸),最近被发现是脂类和胆固醇代谢的有效调节剂。改建 In miR的表达也与内毒素/游离脂肪酸诱导的炎症反应、肝脏脂肪毒性和 胰岛素抵抗与非酒精性脂肪性肝病的临床进展异喹啉黄连素(BBR) 从许多中草药中分离出来的生物碱,已被用于治疗各种感染性疾病超过 在亚洲已经有3000年的历史了。大量研究表明,BBR具有多种药理活性,包括 具有抗炎、降血糖、降脂作用。重要的是,BBR代表了一种新的胆固醇- 通过与目前的他汀类药物治疗不同的独特机制降低药物。这些研究强烈地 提示BBR是治疗NAFLD/NASH的一种有前途的天然药物。然而,分子 BBR的抗炎和降脂作用的机制仍未完全确定。 我们已经证明,补肾活血方通过调节内质网应激介导的肿瘤坏死因子-和IL-6的表达来抑制 巨噬细胞中的RNA结合蛋白(RBP)Hur。MIR研究的最新进展已经确定 作为炎症、脂肪代谢和代谢紊乱的主要调节因子的MIR的特异性小组,如 如miR-155、miR-125a-5p、miR-33、miR-34a和miR-122。此外,据报道,BBR施加了 调节肠道微生物区系对高脂饮食诱导的NAFLD/NASH的保护作用 和胆汁酸代谢。我们的初步研究还表明,1)BBR显著抑制了WD诱导的 动物模型的肝脏脂质堆积和全身炎症;2)BBR抑制FFA诱导的ER 3)BBR抑制FFA诱导的小鼠肝细胞miR-34a表达。 肝细胞和内毒素诱导的巨噬细胞miR-125a-5p的表达;4)miR-34a的表达 C/EBP同源蛋白(CHOP)的表达显著下调,CHOP是内质网应激介导的主要参与者 细胞凋亡)敲除(CHOP-/-)原代肝细胞;5)BBR显著降低WD诱导的 6)内质网应激和内毒素对肠上皮细胞更新的抑制作用 通过删除印章而获救。基于这些观察,我们假设BBR抑制WD- 通过抑制内质网应激和炎症反应诱导肝脏脂肪毒性。以下两个具体内容 为了检验这一假说,我们提出了目标。目标1:确定BBR抑制BBR的机制 脂多糖/游离脂肪酸诱导的内质网应激和肝细胞和巨噬细胞的炎症反应;目的#2: 明确BBR抑制WD诱导的肝脂毒性的机制,并进一步检验其治疗作用 在一种新的体内NAFLD/NASH模型中,BBR对WD诱导的肝脏脂肪毒性的影响。
英文摘要
Nonalcoholic fatty liver disease (NAFLD) has emerged as the most prevalent chronic liver disease, especially among US veterans. NAFLD is critically linked to inflammation, insulin resistance, dyslipidemia, and the metabolic syndrome. Recent advances in NAFLD and non-alcoholic steatohepatitis (NASH) studies indicate that gut microbiota exerts a significant role in the disease progression by affecting host metabolic balance and immune response. The “metabolic endotoxemia” and elevated circulating levels of lipopolysaccharide (LPS) due to disruption of intestinal barrier function and free long chain fatty acids (FFA) are implicated in the stimulation of systemic inflammation and insulin resistance, both of which are positively correlated with the development and progression of NAFLD. Although the mechanism by which LPS/FFA induce hepatic lipotoxicity is still not fully understood, LPS/FFA-induced expression of inflammatory cytokines such as TNF-  and activation of the endoplasmic reticulum (ER) stress signaling pathway, known as the unfolded protein response (UPR), are major contributors. Furthermore, micro-RNAs (miR), small noncoding RNAs (~22 nucleotides), have recently been found to be potent regulators of lipid and cholesterol metabolism. Alterations in miR expression have also been linked to LPS/FFA-induced inflammatory response, hepatic lipotoxicity and insulin resistance as well as disease progression of NAFLD in the clinic. Berberine (BBR), an isoquinoline alkaloid isolated from many medicinal herbs, has been used to treat various infectious disorders for more than 3,000 years in Asia. Numerous studies have shown that BBR has various pharmacological activities including anti-inflammatory, hypoglycemic and lipid-lowering effects. Importantly, BBR represents a novel cholesterol- lowering drug through a unique mechanism distinct from the current statin therapy. These studies strongly indicate that BBR is a promising natural therapeutic agent for NAFLD/NASH. However, the molecular mechanisms underlying BBR’s anti-inflammatory and lipid-lowering properties remain to be fully identified. We have demonstrated that BBR inhibits ER stress-mediated TNF- and IL-6 expression through regulating the RNA-binding protein (RBP) HuR in macrophages. Recent advances in miR research have identified specific panels of miRs as major regulators of inflammation, lipid metabolism and metabolic disorders, such as miR-155, miR-125a-5p, miR-33, miR-34a, and miR-122. In addition, it has been reported that BBR exerted protective effects against high fat Western diet (WD)-induced NAFLD/NASH via modulating gut microbiota and bile acid metabolism. Our preliminary studies also indicate that 1) BBR significantly inhibited WD-induced hepatic lipid accumulation and systemic inflammation in animal models; 2) BBR inhibited FFA-induced ER stress and lipid accumulation in hepatocytes; 3) BBR inhibited FFA-induced miR-34a expression in hepatocytes and LPS-induced miR-125a-5p expression in macrophages; 4) The expression of miR-34a was significantly down-regulated in C/EBP homologous protein (CHOP, a major player of ER stress-mediated apoptosis) knock out (CHOP-/-) primary hepatocytes; 5) BBR significantly reduced WD-induced increase of intestinal permeability; 6) ER stress- and LPS-induced suppression of intestinal epithelial cell renewal was rescued by deletion of the CHOP. Based on these observations, we HYPOTHESIZE that BBR inhibits WD- induced hepatic lipotoxicity by inhibiting ER stress and inflammatory response. The following two specific aims are proposed to test this hypothesis. Aim #1:To determine the mechanism by which BBR inhibits LPS/FFA-induced ER stress and the inflammatory response in hepatocytes and macrophages; Aim #2: To identify the mechanism by which BBR inhibits WD-induced hepatic lipotoxicity and further test the therapeutic effect of BBR on WD-induced hepatic lipotoxicity in a novel in vivo NAFLD/NASH model.
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.livres.2019.02.003
发表时间: 2019-03-01
期刊: Liver research
影响因子: --
作者: [Kwong, Eric K, Zhou, Huiping]
通讯作者: Zhou, Huiping
DOI: 10.3390/cells11081374
发表时间: 2022-04-18
期刊: Cells
影响因子: 6
作者: [Way GW, Jackson KG, Muscu SR, Zhou H]
通讯作者: Zhou H
DOI: 10.3390/cells10112806
发表时间: 2021-10-20
期刊: Cells
影响因子: 6
作者: [Xue R, Su L, Lai S, Wang Y, Zhao D, Fan J, Chen W, Hylemon PB, Zhou H]
通讯作者: Zhou H
DOI: 10.3390/cells12050792
发表时间: 2023-03-02
期刊: Cells
影响因子: 6
作者: []
通讯作者:
共 10 条
    Bile Acids and Sphingosine 1-Phosphate in Non-Alcoholic Steatohepatitis (NASH)
    The ShEEP request for NanoString GeoMx Digital Spatial Profiling and nCounter MAX Complete System
    The ShEEP request for Waters Xevo TQ-XS Liquid Chromatography Mass Spectrometer System
    BLR&D Research Career Scientist Award Application
    国内基金
    海外基金
    Iboga alkaloids骨架导向的不对称串联反应构建吖庚环并[4,5-b]吲哚及其在全合成中的应用
    • 批准号:
      21801032
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      26.0万元
    • 批准年份:
      2018
    • 负责人:
      陈惠渝
    • 依托单位: